ICIsli Cela

Isli Cela

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isli Cela has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhanced Refractive Index Sensitivity of LinearlyAssembled Gold Nanoantennae for BiosensingApplications

    by Taufhik Hossain Tonmoy, Sezer Seçkin, Marisa Hoffmann, Isli Çela, Gyusang Yi, Ahmed Alsadig, Swagato Sarkar, Christian Rossner, Tobias A.F. König, Andreas Fery, et al.

    Near-field interactions between individual gold nanoparticles (AuNPs) in clusters or arrays open a new avenue for highly sensitive plasmonic biosensors, owing to their significant impact on the localized surface plasmon resonance. Compared to individual nanoparticles, supracolloidal structures offer unique plasmonic properties with the enhanced susceptibilities to variations in the local refractive index. In this study, we report on the template-assisted fabrication of large-scale (ca. 1 cm²) linear periodic assemblies of AuNPs and demonstrate their polarization dependent biosensing performance at the proof-of concept level. We explored two complementary approaches for template fabrication: (i) laser interference lithography (LIL), offering high-fidelity patterns over moderate areas, and (ii) wrinkle-assisted patterning, a more scalable and costeffective strategy. Despite structural differences, both approaches yielded comparable high biosensing performances, demonstrating broad potential utility of the developed biosensing platform. As a proof-of-concept application, we performed biofunctionalization and detection of the antibody for Tumor Necrosis Factor-Alpha (TNF-α), a pro-inflammatory cytokine that plays a multifaceted role in cancer prognosis. The shifts in plasmonic resonance peaks of the AuNP assemblies were quantified using polarized-light vis-NIR spectrometry during various stages of the functionalization and detection process. The experimental results revealed a pronounced polarization-dependent plasmonic resonance peak shift (Δλ), with up to a 5-fold increase observed in the longitudinal mode over the transversal case, a feature consistently achieved across both LIL 3 and wrinkled templates. These findings present an innovative supracolloidal structuring approach for the development and scalable production of highly sensitive, plasmonic biochips.

  • Open Access

    Towards Precision CAR T-cell Immunotherapy: extended gate FET biosensor for personalized drug monitoring

    by Trang-Anh Nguyen-Le, Christin Neuber, Isli Cela, Zeljko Janićijević, Liliana Rodrigues Loureiro, Lydia Hoffmann, Anja Feldmann, Michael Bachmann, Larysa Baraban

    Selection and optimization of therapies for cancer patients urgently needs personalization. Portable point-of-care electronic biosensors emerge as a groundbreaking solution to contribute to better decision-making in precision oncology. This study showcases the innovative use of extended gate field-effect transistor (EG-FET) biosensors to monitor the concentration and pharmacokinetics of immunotherapeutic drugs in vivo. Complementary positron emission tomography (PET) and radioactivity biodistribution studies in mice validate the EG-FET measurements. We introduce a novel indirect assay format for detecting target modules in an adapter CAR T-cell therapy model, effectively addressing the limitations of traditional potentiometric measurements. The EG-FET sensors exhibit exceptional sensitivity, and fulfill the requirements for immunotherapeutic drug monitoring without the need for complex radioactive labeling. In pharmacokinetic evaluations, the FET-based biosensor's performance aligns with standard radioactive measurements, revealing the distinct lifespans of small-sized TMs (15 minutes for scFv type) and larger TMs (14 hours for IgG4 type). These promising findings advocate for further exploration of next-generation biosensors in therapeutic monitoring roles. With their cost, size, and response time advantages, these biosensors hold immense potential for advancing personalized oncology, transcending the conventional diagnostic roles typically highlighted in the literature.

  • Open Access

    Breast Cancer Plasticity after Chemotherapy Highlights the Need for Re-Evaluation of Subtyping in Residual Cancer and Metastatic Tissues

    by Irena Barbara Padzińska-Pruszyńska, Muhammad Waqas Akbar, Murat Isbilen, Emilia Górka, Baris Kucukkaraduman, Seçil Demirkol Canlı, Ege Dedeoğlu, Shila Azizolli, Isli Cela, Abbas Guven Akcay, et al.

    This research paper presents a novel approach to identifying biomarkers that can be used to prognosticate patients with triple-negative breast cancer (TNBC) eligible for neoadjuvant therapy. The study utilized survival and RNA sequencing data from a cohort of TNBC patients and identified 276 genes whose expression was related to survival in such patients. The gene expression data were then used to classify patients into two major groups based on the presence or absence of Wingless/Integrated-pathway (Wnt-pathway) and mesenchymal (Mes) markers (Wnt/Mes). Patients with a low expression of Wnt/Mes-related genes had a favorable outcome, with no deaths observed during follow-up, while patients with a high expression of Wnt/Mes genes had a higher mortality rate of 50% within 19 months. The identified gene list could be validated and potentially used to shape treatment options for TNBC patients eligible for neoadjuvant therapy providing valuable insights into the development of more effective treatments for TNBC. Our data also showed significant variation in gene expression profiles before and after chemotherapy, with most tumors switching to a more mesenchymal/stem cell-like profile. To verify this observation, we performed an in silico analysis to classify breast cancer tumors in Prediction Analysis of Microarray 50 (PAM50) molecular classes before treatment and after treatment using gene expression data. Our findings demonstrate that following drug intervention and metastasis, certain tumors undergo a transition to alternative subtypes, resulting in diminished therapeutic efficacy. This underscores the necessity for reevaluation of patients who have experienced relapse or metastasis post-chemotherapy, with a focus on molecular subtyping. Tailoring treatment strategies based on these refined subtypes is imperative to optimize therapeutic outcomes for affected individuals.